Apex Capital Management’s Novo Nordisk NVO Stock Holding History

Apex Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.06M	Buy	39,142 +12,060	+45%	+$323K	0.02%	190
2015 Q4	$786K	Sell	27,082 -1,400	-5%	-$38.8K	0.02%	188
2015 Q3	$772K	Hold	28,482	–	–	0.02%	188
2015 Q2	$780K	Buy	28,482 +6,070	+27%	+$171K	0.02%	195
2015 Q1	$598K	Buy	22,412 +1,162	+5%	+$26.8K	0.01%	207
2014 Q4	$450K	Hold	21,250	–	–	0.01%	225
2014 Q3	$506K	Hold	21,250	–	–	0.02%	207
2014 Q2	$491K	Buy	21,250 +4,350	+26%	+$96K	0.02%	219
2014 Q1	$386K	Hold	16,900	–	–	0.01%	235
2013 Q4	$312K	Buy	+16,900	New	+$295K	0.01%	232

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Apex Capital Management's NVO Position: Q1 2016 in Review

Apex Capital Management increased its Novo Nordisk (NVO) stake by 45% in Q1 2016, buying an estimated $323K and bringing the position to 39,142 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #190.

Apex Capital Management first reported a position in NVO in Q4 2013 and has held it in 10 quarters since. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

Apex Capital Management held 39,142 shares of Novo Nordisk worth $1.06M as of Q1 2016.
Apex Capital Management bought 12,060 Novo Nordisk shares in Q1 2016, an estimated $323K.
Novo Nordisk made up 0.02% of Apex Capital Management's portfolio in Q1 2016, its #190 holding.
Apex Capital Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 10 quarters since.
535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.